Los Angeles Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Los Angeles Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.5K	Hold	103	–	–	﹤0.01%	2276
2026 Q1	$1.3K	Hold	103	–	–	﹤0.01%	2326
2025 Q4	$1.12K	Buy	+103	New	+$1.31K	﹤0.01%	2474
2021 Q2	–	Sell	-4,810	Closed	-$237K	–	1573
2021 Q1	$237K	Sell	4,810 -10,545	-69%	-$526K	﹤0.01%	1497
2020 Q4	$646K	Sell	15,355 -1,925	-11%	-$84.7K	﹤0.01%	1104
2020 Q3	$791K	Hold	17,280	–	–	﹤0.01%	911
2020 Q2	$868K	Sell	17,280 -125	-0.7%	-$6.47K	﹤0.01%	902
2020 Q1	$895K	Sell	17,405 -18,125	-51%	-$966K	0.01%	737
2019 Q4	$2.19M	Sell	35,530 -15,212	-30%	-$943K	0.01%	624
2019 Q3	$3.05M	Sell	50,742 -18,360	-27%	-$1.36M	0.02%	525
2019 Q2	$5.83M	Buy	69,102 +63,742	+1,189%	+$5.73M	0.03%	412
2019 Q1	$512K	Buy	5,360 +1,070	+25%	+$96K	﹤0.01%	1072
2018 Q4	$304K	Buy	4,290 +650	+18%	+$49.8K	﹤0.01%	1095
2018 Q3	$311K	Buy	+3,640	New	+$365K	﹤0.01%	1214

Other funds holding ENTA

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KAM

Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SSC

Spruce Street Capital New York $510M AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Los Angeles Capital Management's ENTA Position: Q2 2026 in Review

Los Angeles Capital Management held its Enanta Pharmaceuticals (ENTA) position steady in Q2 2026 at 103 shares worth $1.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2276.

Los Angeles Capital Management first reported a position in ENTA in Q3 2018 and has held it in 14 quarters since. The position peaked at $5.83M in Q2 2019. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

Los Angeles Capital Management held 103 shares of Enanta Pharmaceuticals worth $1.5K as of Q2 2026.
Los Angeles Capital Management left its Enanta Pharmaceuticals share count unchanged in Q2 2026.
Enanta Pharmaceuticals made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #2276 holding.
Los Angeles Capital Management first reported a position in Enanta Pharmaceuticals in Q3 2018 and has held it in 14 quarters since.
Los Angeles Capital Management's Enanta Pharmaceuticals position peaked at $5.83M in Q2 2019.
123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.